medigraphic.com
ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2011, Number 5

Next >>

Salud Mental 2011; 34 (5)

Tratamiento multimodal de niños y adolescentes con depresión

Ulloa-Flores RE, de la Peña-Olvera F, Nogales-Imaca I

Language: Spanish
References: 37
Page: 403-407
PDF size: 74.94 Kb.


ABSTRACT

Major Depressive Disorder (MDD) in children and adolescents is a common and impairing condition that is both recurrent and persistent into adulthood. In this article, a review of the literature regarding multimodal treatment is presented.
The literature review process for this article included «adolescents», «children», «depression», «treatment», «antidepressants» and «psychotherapy» as key words. The initial Medline search covered a 10 year period dating back to 2001. Double blind randomized and meta-analysis studies were considered as gold standard to be included in the revision, but also experts’ consensus were incorporated.
Regarding pharmacological treatment, tricyclic-antidepressants did not show better efficacy against placebo in double blind controlled studies; selective serotonin reuptake inhibitors showed better efficacy against placebo in controlled studies, specifically fluoxetine and escitalopram, both approved to be used in pediatric population with MDD. Noradrenalin and serotonin reuptake inhibitors like venlafaxine or mirtazapine had not shown superior response than placebo. Comorbidity needs to be taken into account in the decisions of the pharmacological treatment; attention deficit hyperactivity disorder is the most frequent associated disorder and requires to add specific drug treatment like stimulants; if psychotic symptoms are present, atypical antipsychotics should be added.
Regarding psychosocial treatment, psychoeducation is the first step in this treatment approach. Psychotherapy aims include decreasing symptoms severity by improving self esteem, increasing frustration tolerance and autonomy, as well as the ability to enjoy daily life activities, and establishing good relations with peers. Interpersonal and cognitive behavioral therapies are good options as psychotherapy for this age group. It is important to monitor patients to prevent relapses and complications of depression and suicidal behavior.


REFERENCES

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). IV Edición. Washington, DC; 1994.

  2. Organización Mundial de la Salud. Programa mundial de acción en salud mental; 2002. Consultado en http://www.who.int/mental_health/media/en/267.pdf el 22 junio 2010.

  3. Birmaher B, Ryan N, Williamson D, Brent D et al. Childhood and adolescent depression: A review of the past ten years. Part I. J Am Child Adolesc Psychiatry 1996;35:1427-1439.

  4. Kashani J, Carlson G, Beck N, Hoeper E et al. Depression, depressive symptoms, and depressed mood among a community sample of adolescents. Am J Psychiatry 1987;144:931-934.

  5. Whitaker A, Johnson J, Shaffer D, Rapoport J et al. Uncommon troubles in young people: Prevalence estimates of selected psychiatric disorders in a nonreferred adolescent population. Arch Gen Psychiatry 1990;47: 487-496.

  6. Benjet C, Borges G, Medina-Mora M, Méndez E et al. Diferencias de sexo en la prevalencia y severidad de trastornos psiquiátricos en adolescentes de la Ciudad de México. Salud Mental 2009;32:155-163.

  7. Nogales I, Ulloa R, Rodríguez H, Palacios L et al. Depresión en niños y adolescentes. En: Ulloa R, Fernández C, Gómez H, Ramírez J, Reséndiz J (eds). Guías clínicas. México DF.: Hospital Psiquiátrico Infantil Dr. Juan N. Navarro; 2010; pp.63-85.

  8. Zisook S, Lesser I, Stewart J, Wisniewski S et al. Effect of age at onset on the course of major depressive disorder. Am J Psychiatry 2007;164:1539-1546.

  9. Angst J. The course of affective disorders. II: Typology of bipolar manic- depressive illness. Arch Psychiat Nervenkr 1978;226:65-73.

  10. Hughes C, Emslie G, Crismon M, Posner K et al. Texas children’s medication algorithm project: update from Texas consensus conference panel on medication treatment of childhood major depressive disorder. J Am Acad Child Adolesc Psychiatry 2007;46:667-686.

  11. Maalouf F, Brent D. Pharmacotherapy and psychotherapy of pediatric depression. Expert Opin Pharmacother 2010;11:2129-2140.

  12. Varley C. Sudden death related to selected tricyclic antidepressants in children: epidemiology, mechanisms and clinical implications. Paediatr Drugs 2001;3:613-627.

  13. Hazell P. Depression in children and adolescents. Clin evid 2009;01:1008. Consultado en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907806/?tool=pubmed el 10 enero 2011.

  14. Emslie G, Heiligenstein J, Hoog S, Wagner K et al. Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 2004;43:1397-1405.

  15. Attari A, Moghaddam Y, Hasanzadeh A, Soltani M et al. Comparison of efficacy of fluoxetine with nortriptyline in treatment of major depression in children and adolescents: A double-blind study. J Res Med Sci 2006;11:24-30.

  16. Riggs P, Mikulich-Gilbertson S, Davies R, Lohman M et al. A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders. Arch Ped Adolesc Med 2007;161:1026-1034.

  17. Yang L, Scott L. Escitalopram: in the treatment of major depressive disorder in adolescent patients. Paediatr Drugs 2010;12:155-163.

  18. Usala T, Clavenna A, Zuddas A, Bonati M. Randomised controlled trials of selective serotonin reuptake inhibitors in treating depression in children and adolescents: a systematic review and meta-analysis. Eur Neuropsychopharmacol 2008;18:62-73.

  19. Melvin G, Tonge B, King N, Heyne D et al. A comparison of cognitivebehavioral therapy, sertraline, and their combination for adolescent depression. J Am Acad Child Adolesc Psychiatry 2006;45:1151-1161.

  20. National Institute for Health and Clinical Excellence. Depression in children and young people. Identification and management in primary, community and secondary care; 2005. Consultado en: www.nice.org.uk/guidance/CG28/niceguidance/pdf/English and http://www.bps.org.uk/document-download-area/document-download$.cfm?file_uuid=C6AF4F6E-1143-DFD0-7E1D-44F57ED65DB4&ext=zip el 6 enero 2011.

  21. Valluri S, Zito J, Safer D, Zuckerman I et al. Impact of the 2004 food and drug administration pediatric suicidality warning on antidepressant and psychotherapy treatment for new-onset depression. Med Care 2010;48:947-954.

  22. Emslie G, Findling R, Yeung P, Kunz N et al. Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebocontrolled trials. J Am Acad Child Adolesc Psychiatry 2007;46:479-488.

  23. Vitiello B, Emslie G, Clarke G, Wagner K et al. Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample. J Clin Psychiatry 2011;72(3):388-396.

  24. Glod C, Lynch A, Flynn E, Berkowitz C et al. Open trial of bupropion SR in adolescent major depression. J Child Adolesc Psychiatr Nurs 2003; 16:123-130.

  25. Solhkhah R, Wilens T, Daly J, Prince J et al. Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit/ hyperactivity disorder and mood disorders. J Child Adolesc Psychopharmacol 2005;15:777-786.

  26. David-Ferdon C, Kaslow N. Evidence-based psychosocial treatments for child and adolescent depression. J Clin Child Adolesc Psychol 2008;37:62-104.

  27. Klein J, Jacobs R, Reinecke M. Cognitive-behavioral therapy for adolescent depression: a meta-analytic investigation of changes in effect-size estimates. J Am Acad Child Adolesc Psychiatry 2007;46:1403-1413.

  28. Langer D, Chiu A, Asarnow J. How to use cognitive behavior therapy for youth depression: A guide to implementation. En: Rey J, Birmaher B (eds). Treating child and adolescent depression. Baltimore, MD: Lippincott Williams & Wilkins; 2009; pp.100-113.

  29. Birmaher B, Brent D, Kolko D, Baugher M et al. Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder. Arch Gen Psychiatry 2000;57:29-36.

  30. Stice E, Rohde P, Gau J, Wade E. Efficacy trial of a brief cognitive-behavioral depression prevention program for high-risk adolescents: effects at 1- and 2-year follow-up. Consult Clin Psychol 2010;78:856-867.

  31. Mufson L, Verdeli H, Clougherty K, Shoum K. How to use interpersonal psychotherapy for depressed adolescents (IPT-A). En: Rey J, Birmaher B (eds). Treating child and adolescent depression. Baltimore, MD: Lippincott Williams & Wilkins; 2009; pp.114-127.

  32. Gunlicks-Stoessel M, Mufson L, Jekal A, Turner J. The impact of perceived interpersonal functioning on treatment for adolescent depression: IPT-A versus treatment as usual in school-based health clinics. J Consult Clin Psychol 2010;78:260-267.

  33. Young J, Mufson L, Gallop R. Preventing depression: a randomized trial of interpersonal psychotherapy-adolescent skills training. Depress Anxiety 2010;27:426-433.

  34. Horowitz J, Garber J, Ciesla J, Young J et al. Prevention of depressive symptoms in adolescents: a randomized trial of cognitive-behavioral and interpersonal prevention programs. J Consult Clin Psychol 2007;75: 693-706.

  35. Tang T, Jou S, Ko C, Huang S et al. Randomized study of school-based intensive interpersonal psychotherapy for depressed adolescents with suicidal risk and parasuicide behaviors. Psychiatry Clin Neurosci 2009;63:463-470.

  36. Curry J, Silva S, Rohde P, Ginsburg G et al. Recovery and recurrence following treatment for adolescent major depression. Arch Gen Psychiatry 2011;68:263-269.

  37. Dubicka B. Combined treatment with cognitive-behavioural therapy in adolescent depression: meta-analysis. Br J Psychiatry 2010;197:433-440.




2020     |     www.medigraphic.com